Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELACOEUR: Belatacept in Cardiac Transplant Patients at Risk of Chronic Renal Failure
NCT04180085Phase 2Recruiting
- Sponsor
- CHU de Nantes
- Start
- Feb 2020
- Primary completion
- Jan 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belatacept in cardiac allograft failure (CAF) and chronic kidney disease (CKD), sponsored by CHU de Nantes. Primary endpoint: Glomerular Filtration Rate Clearance at 12 months. Started Feb 2020; status: recruiting.
02
Drugs
belatacept
03
Conditions
cardiac allograft failure (CAF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04180085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04180085.